The fraction of cells with a migratory phenotype (F-actin-positive, extending pseudopods) was strongly reduced (from 50% to 13% at day 10), while the number of apoptotic and mitotic cells remained unchanged. Endostatin also hampered the recruitment of -smooth muscle actin-expressing perivascular cells and thus reduced the number of mature vessels (from 64.3% to 28.6% at day 30). Moreover, transcripts of pericyte-recruiting platelet-derived growth factor-B (PDGFB) were strongly reduced in endothelial cells of endostatin-treated mice. Our results are strong evidence that endostatin inhibits angiogenesis at several levels in vivo including perivascular cell recruitment.
Introduction
The formation of new capillaries from preexisting vessels (angiogenesis) appears to be essential for tumor growth and survival [1] [2] [3] [4] [5] [6] . Whereas hypoxic conditions in expanding tumors often initiate a cascade of endothelial cell sprouting and formation of new vessels, tumor growth can be arrested by inadequate blood supply and a lack of metabolic exchange, often leading to tumor necrosis and regression 7 .
Several tumor-derived, circulating angiogenesis inhibitors generated in vivo by proteolytic degradation, have been recently identified (reviewed in 8, 9 ). In particular, a 20 kDa C-terminal proteolytic fragment of collagen XVIII, termed endostatin, inhibits tumor growth in several animal models [10] [11] [12] [13] [14] [15] . Although the mechanisms of action are incompletely understood, endostatin reportedly interacts with several endothelial cell surface receptors that are critically involved in angiogenesis. Endostatin binds directly to the fibronectin receptor 5 1 16,17 and also interacts with v 3 and v 5 integrins 17 . In keeping with these interactions, endostatin inhibits endothelial cell binding to the v 3 -ligand gelatin 17 , and also their binding to collagen type I in a dose-dependent manner 18 . Moreover, endostatin binds to heparan sulfate [19] [20] [21] [22] , tropomyosin 23 , caveolin-1 16 VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1) 24 and was recently shown to depend on E-selectin expression to be effective in vivo 25 . Interaction of endostatin with endothelial cells leads to a variety of downstream effects [26] [27] [28] , including inhibition of the Wnt/ -catenin pathway 29 , and actin re-organization in endothelial cells 16, [30] [31] [32] [33] . In fact, this wide variety of effects elicited by one endogenous inhibitor of angiogenesis was recently supported by two studies of global gene expression in endostatin-treated endothelial cells 27, 34 .
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From There is general agreement that the in vitro action of endostatin involves inhibition of endothelial cell migration, but less clear whether endostatin also affects endothelial cell apoptosis and proliferation 6, 12, 26, [35] [36] [37] [38] [39] . Furthermore, even less is known about how endostatin affects endothelial cell function in vivo, as readouts have been restricted to analysis of vascular density or blood flow in tumors [12] [13] [14] 35, 40 , or neovascularization of the chick allantoic membrane 10, 12, 39 . Moreover, studies that focused in more detail on endothelial cell behavior in vivo either failed to detect substantial effects of endostatin 41 or found subtle signs of impaired blood vessel maturation 42 . Finally, several studies failed to observe an anti-tumor effect of endostatin (reviewed in 43 ). Thus, there is an obvious need to more carefully analyze the effect of endostatin at the level of single endothelial cells during angiogenesis.
Here we describe the effect of endostatin in an in vivo model of human endothelial cell behavior in which the final stages of angiogenesis, i.e. assembly of single endothelial cells to complex microvessels, can be observed directly. In the absence of endostatin, human endothelial cells suspended in Matrigel form complex human vessels that make xenogeneic contact with the murine vascular system, carry murine blood and recruit perivascularsmooth muscle actin-positive cells 44 . However, systemic delivery of yeast-derived, recombinant human endostatin leading to serum levels of 30-35 ng/ml during 30 days almost completely abolished endothelial cell migration and capillary morphogenesis, and also inhibited the recruitment of perivascular cells. Laboratories (Burlingame, CA). Rhodamine-conjugated phalloidine (R415) was from Molecular Probes (Eugene, OR).
Primary antibodies and secondary reagents
The primary antibodies (Abs) used in this study were mouse anti-human CD31 (hec7, 0.4 µg/ml, courtesy of W. A. Muller), mouse anti-human Ki67 (MIB-1, 10 µg/ml, Dako, Glostrup, Denmark), mouse anti--smooth muscle actin (M0851, 10 µg/ml, Dako) and rabbit anti-TGF 1 (10 µg/ml, Promega, Phoenix, AZ). Irrelevant control Abs raised to tomato or potato viruses, respectively, were matched for concentration and isotype (courtesy of R.
Burns, Edinburgh). Texas red (TR)-conjugated donkey anti-mouse IgG (H+L) and
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From Streptavidin-Cy3 were from Jackson ImmunoResearch Laboratories (West Grove, PA), and biotinylated donkey anti-rabbit IgG (H+L) was from Vector Laboratories.
In vivo experiments
Animal experiments were performed in accordance with institutional guidelines and national legislation. Specific pathogen-free (SPF) BALB/c Rag2 -/-mice (age: 6-8 weeks, weight: 20-22 g) were purchased from Taconic (Ry, Denmark), and fed BK001 pelleted rat and mouse diet (Grimston, Aldbruugh, Hull) and tap water ad libitum. Anesthesia was induced by i.p. Upon termination of the experiment, the Matrigel plugs were removed by a wide excision of the abdominal wall, including the skin and all muscle layers, and transferred to PBS on ice.
Each specimen was then divided into two pieces, one being immediately snap-frozen (liquid N 2 ) in OCT compound for storage at -70°C until use, the other being fixed for 24 h in 
RT-PCR analysis
Matrigel plugs were harvested on ice and separated from surrounding mouse tissue with a scalpel. The plugs were cut into small pieces and digested in collagenase 1 mg/ml and dispase 2 mg/ml dissolved in EBM (40 min, 37°C) on a magnetic stirrer. The cell suspension was next washed twice with PBS (4°C), sequentially incubated with mouse anti-hCD31 antibody (15 min on ice) and para-magnetic Dynabeads coated with rat anti-mouse IgG (20 min, 4°C on a roller) before extraction of human endothelial cells. Total RNA isolation and on-column DNase treatment was performed using the RNeasy Mini Kit according to instructions of the manufacturer (Qiagen GmbH, Hilden, Germany). Total RNA was reverse transcribed using Oligo(dT) and Superscript III Reverse Transcriptase (Invitrogen, USA). Human plateletderived growth factor-B (PDGFB) and transforming growth factor-(TGF ) mRNA transcripts were quantified by real-time PCR using the Light Cycler (Roche Diagnostics).
TGF copy numbers were quantified by using the TGF-1 kit from Search-LC (GmbH, Heidelberg, Germany) according to instructions of the manufacturer. Human PDGFB specific transcripts were amplified using 5'-CAT AGA CCG CAC CAA CGC CAA CTT C-3' as forward primer and '5-ATC TTT CTC ACC TGG ACA GGT CGC AG-3' as reverse primer at 3.0 mM MgCl 2 and 68°C annealing temperature. Copy numbers were determined using the standard from the PDGF-LightCycler kit from Search-LC. As internal control for the amount of human RNA input we quantified the human housekeeping gene hydroxymethylbilane synthase using the QuantiTect SYBR Green PCR kit (Qiagen GmbH) at 
Immunostaining protocols
All of the following steps were performed at 22°C unless otherwise noted. Frozen tissue sections (8 µm) were air-dried overnight and subsequently acetone-fixed (10 min). Paraffin sections (4 µm) were dried for 24 h at 4°C, dewaxed with xylene (10 min), and rehydrated through graded alcohols before staining. Cryosections were incubated with the primary and secondary reagents for 1 hour each, whereas paraffin sections were incubated with primary Abs for 20 hours, secondary reagents for 3 hours and tertiary reagents for 1 hour respectively.
Tissue sections were immunostained with a mixture of primary mouse Abs and FITCconjugated Ulex lectin (10 µg/ml), next with TR-conjugated donkey anti-mouse IgG. In other protocols we either combined FITC-conjugated Ulex lectin with rhodamine-conjugated phalloidin (1/200). Detection of TGF 1 was performed by microwave-treatment of the tissue sections before incubation with an antibody to TGF 1 in combination with FITC-conjugated ULEX lectin followed by biotinylated donkey anti-rabbit IgG (7.5 µg/ml) and finally Streptavidin-Cy3 (0.5 µg/ml).
The ApopTag kit was used to detect apoptotic cells in the Matrigel plugs, based on the TUNEL assay by detection of nuclear DNA fragmentation 47 . Peroxidase staining of pretreated cryosections was done as described by the manufacturer's instructions. Positive cells were counted in gels in both treated and untreated groups.
Negative controls were tissue sections incubated with primary irrelevant isotype-and concentration-matched Abs, whereas tissue sections from human tonsils or lingual cancer equipped with a F-view digital camera controlled by the analySIS 3.2 software (Soft Imaging System GmbH, Munster, Germany).
In situ determination of PDGFB in human endothelium
One kb digoxigenin (DIG)-labeled sense and antisense riboprobes were generated from the coding region of human PDGFB with a DIG RNA labeling kit according to the manufacturer's directions (Boehringer Mannheim), and applied to air dried (60°C, over night), formalin fixed paraffin sections (4 µm) after dilution in RiboHybe (Ventana Medical Systems, Illkirch, France). Deparaffinization, pretreatment and hybridization were performed according to manufacturer's instructions on a Ventana Discovery automated histology robot (Ventana). Pretreatment consisted of mild alkaline protease (0.02 U/ml, 4 min, 37°C) and Ribo CC (mild protocol). Hybridization was performed at 60°C (6 h) and stringency washes with three rounds of 2X SSC (6 min, 60°C). Riboprobes were detected with biotinylated antiDigoxin (Jackson, 1:500, 32 min, 37°C) and the BlueMap Kit (Ventana) that develops the NBC/BCIP alkaline phosphatase substrate.
ELISA determination of osmotic pump-delivered endostatin
Blood samples were collected after 20, 30 and 40 days from the tail artery. Serum levels of human endostatin were quantified by an ELISA that according to the manufacturer's instructions shows less than 5 % cross-reactivity with murine endostatin. 
Results

Serum levels of endostatin
To test the capability of osmotic pumps to deliver endostatin (systemic release of 2 µg/h resulting in 2 mg/kg/day) throughout the experiment, we measured serum levels of human endostatin by means of the EIA ELISA kit, finding that the endostatin levels decreased from 36.4 ± 5.3 ng/ml (mean ± SEM) at day 20 to 29.7 ± 3.6 ng/ml at day 30 ( Fig. 1) , perhaps reflecting the reduction of serum levels upon exhaustion of the pump capacity as they were designed for 28 days delivery. However, endostatin remained detectable at lower levels at day 40 (22.0 ± 3.8 ng/ml). Serum levels from control littermates (pumps releasing saline) were at all timepoints below the detection limit of the assay (data not shown), which in our hands was estimated to 7 ng/ml.
Endostatin inhibits vascular morphogenesis of human endothelial cells in vivo
We have previously shown that adoptively transferred HUVECs suspended in Matrigel form functional human vessels that make xenogeneic contact with the murine vascular system, carry mouse blood and recruit vascular smooth muscle cells 44 . Human endothelial cells were unambiguously discriminated from murine endothelial cells by Ulex binding to the former.
Thus, in the absence of endostatin, single, Ulex-positive HUVECs developed in the predicted manner to initially extend pseudopods and form vessel-like structures within 10 days, predominantly in the periphery of cross-cut matrigel sections. By day 20, 50% of the vessels were considered mature as they were covered by -smooth muscle actin-positive cells or contained erythrocytes (Fig. 2) . By day 30 more human vessels contained erythrocytes and 64.3 % were covered by -smooth muscle actin-positive cells. On day 40 nearly all human
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To quantitatively assess the effect of endostatin on vascular morphogenesis, we counted (Fig. 3) . Thus, the mean ratio at day 20 was 1.03
(range: 1.02 -1.04, n = 2) for the control group, and 0.05 (range: 0.03 -0.07, n = 2) for the endostatin group. By day 30, the mean ratio for the control group was 11.52 (range: 0.40 -51.75, n = 6), whereas the ratio in the endostatin-treated mice remained almost unaltered (mean: 0.07, range: 0.03 -0.14, n = 6). For mock-treated mice in the day 40 group, the mean was 21.62 (range: 0.56 -70.25, n = 6), and for the endostatin-treated mice 0.11 (range: 0.03 -0.18, n = 6) (Fig. 3) . The differences between the endostatin and control groups obtained at day 30 and 40 were significant (p = 0.004 for both groups) using the Mann-Whitney U test.
To further investigate the effects of endostatin on human endothelial cell function in vivo, we also used microvascular endothelial cells derived from nasal polyps (PMECs) in some experiments. These endothelial cells behaved similarly to HUVECs in that they extended To associate the apparently migrating endothelial cell phenotype (i.e. pseudopod extension) with a molecular marker of cell migration, we stained tissue sections with phalloidin to detect polymerized F-actin, as assembly of actin polymers appears to be an absolute requirement for pseudopod extension and cell migration [48] [49] [50] . F-actin was strongly expressed in single cells that extended pseudopods at days 1 and 10, whereas cells of the round phenotype at all timepoints had a weak or almost absent expression of F-actin (Fig. 4 b) . Moreover, mature vessel structures strongly expressed F-actin at all timepoints (data not shown). We therefore This interpretation is well in line with the recent description of a F-actin-positive, migrating endothelial tip cell phenotype that is seen at the tips of vascular sprouts during retinal angiogenesis 51 as well as in sprouting angiogenesis of the zebrafish embryo 52 .
These two distinct endothelial phenotypes were also found in Matrigel plugs in mice treated with endostatin, but in these animals, single cells at day 10 were mainly of the round, F-actinnegative phenotype as only 13 % of the cells extended pseudopods (median, range: 4.9 %-13.5 %, n = 3). This was even more pronounced at day 20 and beyond when gels of endostatin-treated animals remained populated by single cells of which only 1 -3 % were of the pseudopod-extending phenotype (Fig. 4 a) .
Endostatin inhibits maturation of human vessels
In addition to acting as an antiangiogenic agent by dramatically reducing the number of human vascular constructs, endostatin also altered their subsequent maturation into functional vessels. Thus, endostatin also affected the occurrence of -smooth muscle actin-expressing cells, as these were not observed at day 20, and only occurred on a small number of vessels at day 30 (28.6 % in the presence of endostatin vs. 64.3 % in the untreated group, median values, n = 6, p = 0.091, Fig. 5 ). Furthermore, although a substantially higher fraction of human vessels were covered by -smooth muscle actin-positive cells at day 40 than at day 30 (83.1 % vs. 28.6 %), it was nevertheless a lower fraction than in their untreated counterparts (94.5 %, n = 6, p = 0.089) (Fig. 5) . Moreover, human vessels containing erythrocytes were never observed in endostatin treated mice.
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To investigate the possible mechanisms that may have reduced the ratio of -smooth muscle actin-positive cell covered vessels due to endostatin treatment we analyzed endothelial cellexpressed PDGFB (currently considered the most important recruiter of pericytes during angiogenesis 53, 54 ), by means of in situ hybridization. As our probe revealed some hybridization to mouse PDGFB, we co-stained with FITC-labeled Ulex lectin to relate the signal to human endothelium in the Matrigel. While PDGFB transcripts were found in most vascular constructs in both groups, the single, round cells that dominate the gels of endostatintreated mice were negative ( Fig. 6 a and b) . To more accurately quantify the mRNA levels of hPDGFB at days 10 and 20 we also performed quantitative PCR based on mRNA from immunopurified human endothelial cells of enzyme-digested Matrigel plugs. In line with our in situ observations, we found that endostatin reduced the copy numbers of hPDGFB by 90 % and 70 % at days 10 and 20 respectively (Fig. 7 a) .
We also analyzed the expression of TGF , which is known to be an important mediator of mural cell differentiation 54 . We first co-stained with Ulex and an antibody to TGF 1 finding that all human endothelial cells were positive at all stages and in both groups ( Fig. 6 c and d) .
Furthermore, we analyzed the mRNA levels of hTGF , finding the levels to be considerably lower than those of hPDGFB in all samples, and slightly increased in endostatin-treated mice compared to the non-treated mice (Fig. 7 b) .
To control for the amount of human mRNA following isolation we measured the human housekeeping gene hydroxymethylbilane synthase, and found no differences between the samples (data not shown). 
Endostatin has no effect on proliferation and apoptosis of endothelial cells in vivo
To test if HUVEC proliferation was affected by endostatin treatment, we stained for Ki67, a nuclear antigen expressed by proliferating cells, but downregulated in cells reentering the G 0 phase, and therefore suitable for comparing the growth fraction in the two groups 55 . To this end, we counted the number of Ki67-positive cells and related them to the corresponding gel areas. We subsequently tested independence of the obtained ratios and found no differences between the endostatin-and saline-treated groups at days 10 (n = 1), 20 (n = 2) 30 (n = 6, p = 0.15) and 40 (n = 6, p = 0.63) (Fig. 8 a) .
To determine if endostatin induced apoptosis of HUVECs in the Matrigel plug we used the ApopTag kit which detects DNA fragmentation in cells that are apoptotic or pre-apoptotic using the TUNEL method 47 . When counting positive cells in the Matrigel plug and relating them to the cross-cut area, we found the number of apoptotic cells in the plugs to be low (0-5 cells per cross-section at all timepoints), and a difference between the endostatin-and the saline-treated group was not observed at days 10 (n = 1), 20 (n = 2) 30 (n = 6, p = 0.41) and 40 (n = 6, p = 0.80) (Fig. 8 b) . which reported an effect on apoptosis and mitosis exposed their endothelial cell cultures to substantially higher doses of endostatin than we observed in the serum of our mice 10, 26, 37, 38 .
This interpretation would also fit in vitro studies which used endostatin in the nanogram range, and in which case only migration was affected 19, 36 .
The effect of endostatin on endothelial cell migration deserves further discussion, in particular because lack of vascular assembly does not exclude the possibility that single endothelial cells were still capable of random, non-directed migration. However, the strong reduction of cells 
al. reported an initial increase in actin polymerization followed by a decrease to initial levels 30 . Moreover, Keezer et al. showed that endostatin reduced the levels of the actin-depolymerizating protein cofilin and also induced decreased activity of the actincapping protein hsp27 through phosphorylation leading to a weakening of actin stress fibers 32 . Although these reports used different sets of experimental in vitro conditions, they nevertheless fit nicely with our data showing that endostatin in a 3D gel in vivo situation will maintain cells in a state with low numbers of stress fibers, and apparently reduce their ability to extend migratory cellular protrusions.
Our study provides new insight to how endostatin affects in vivo angiogenesis because previous detailed analyses in growing tumors or healing wounds have either failed to detect an effect of endostatin 41 , observed subtle signs of vascular dysfunction 42 or a reduction of global parameters such as vascular density, perfusion and vessel diameter 57 . Our finding that endostatin also affects mural cell recruitment and maturation into circulated vascular constructs adds substantially to the current understanding of how endostatin works in vivo.
Moreover, by showing that endothelial cells in endostatin-treated mice are strongly restricted in their ability to synthesize PDGFB we provide a molecular hypothesis in line with the well documented role of PDGFB on mural cell recruitment 53, 54 . On the other hand, we cannot rule out that endostatin also has a direct effect on perivascular precursor recruitment. Moreover, our data are at variance with those of two recent studies in which cultured endothelial cells were exposed to endostatin but did not alter their expression level of PDGFB 27, 34 (A.
Abdollahi personal communication). Thus, extensive comparison of in vivo and in vitro
expression profiles associated with endostatin-treatment deserves further attention.
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The vascular morphogenesis that became evident after 40 days can be explained by reduced levels of endostatin due to the exhaustion of the osmotic pumps that were designed for delivery up to 28 days. However, the endostatin levels measured in serum on day 40 were only reduced about 40% from those found on day 20. Given that the half-life of human recombinant endostatin in man has recently been found to be 10.7 h 58 , and that a similar halflife might be expected in mice, one may assume that the delivery of endostatin may indeed have exceeded 28 days, perhaps with decreasing amounts. We therefore cannot exclude that the remodeling observed might reflect an override of the mechanisms inhibited by endostatin by exploiting redundant, endostatin-insensitive molecular pathways for vascular assembly.
While this study is focused on observing human endothelial cell behavior in the presence of endostatin, it is perfectly possible that human endostatin also affects the behavior of other In conclusion, this study strongly indicates that the in vivo effect of endostatin on human endothelial cell behaviour is severalfold as we found both migration, vascular morphogenesis and perivascular cell recruitment to be strongly affected. However, it remains to be seen if endostatin administered past 30-40 days for example by exchanging the osmotic pump maintains its angiostatic effect. Furthermore, it will be interesting to examine the effect of other dose levels and regimens in our model including for example the effect on immature vessels that have assembled in the absence of endostatin. Finally, the apparent ability of endostatin to affect vascular maturation deserves increased focus. 
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